In a significant stride for improving oncology treatment, Baysient® has announced its latest innovation: a groundbreaking therapeutic drug monitoring (TDM) software tailored for oncology drugs, coming soon in 2024. This TDM solution takes a Compuceutical approach, merging advanced cloud-based software…
The complexities of Psoriatic Arthritis (PsA) demand a tailored approach to treatment. With the diverse patient responses to medications, a one-size-fits-all strategy is not viable. Enter Baysient’s groundbreaking software applications, iDose® and T3®, which are redefining the therapeutic drug monitoring…
In an era where personalized medicine is to become the rule rather than the exception, pharmacokinetic (PK)-guided dosing is emerging as a crucial practice for enhancing treatment outcomes. Despite its potential to revolutionize healthcare, PK-guided dosing remains underutilized in clinical…
The treatment of rheumatoid arthritis (RA) can no longer be viewed as a one-size-fits-all approach. Each patient's individual characteristics and responses to medication can dramatically influence their treatment outcome. As a result, the old method of standard dosing has proven…
Gastroenterologists often face challenges in managing complex gastrointestinal conditions like ulcerative colitis and Crohn's disease. The key to successful treatment often lies in precision dosing and personalized medicine. Baysient's iDose® and T3® software applications change the game in therapeutic drug…
Built to provide individualized treatments for patients with improved outcomes, Baysient develops SaaS, cloud-based software that provides medical providers with a full line of individual dosage-determination products. Physicians can harness the power of iDose® and T3®, our innovative web-based applications,…
The COVID-19 pandemic has taken a toll on patients and healthcare providers alike, but for patients with inflammatory diseases treated with therapeutic monoclonal antibodies (mAbs), it poses an additional challenge. Baysient's Chief Scientific Officer, Diane Mould, PhD, FCP, FAAPS, recently…
Baysient announces updates to its therapeutic drug monitoring app Time To Target (T3) to enable clinicians to deliver personalized dosing recommendations for the subcutaneous forms of Infliximab and adalimumab. Inflammatory bowel disease (IBD) is a chronic condition affecting approximately 3…
The right dose at the right time is critical for any patient living with a disease. Precision dosing has become a widely discussed topic, and a growing literature recognizes the implications of imprecise dosing on public health, related to both cost…
For patients living with inflammatory bowel disease (IBD), Infliximab (IFX), a monoclonal antibody, has emerged as an efficient treatment for disease activity reduction and IBD patient life quality improvement. However, while IFX is an effective treatment for some patients, a…
